مصطلحات الفهرس: imatinib/dt [Drug Therapy], imatinib/pv [Special Situation for Pharmacovigilance], lapatinib/ae [Adverse Drug Reaction], lapatinib/dt [Drug Therapy], lapatinib/pv [Special Situation for Pharmacovigilance], sorafenib/dt [Drug Therapy], sorafenib/pv [Special Situation for Pharmacovigilance], sunitinib/ae [Adverse Drug Reaction], sunitinib/dt [Drug Therapy], sunitinib/pv [Special Situation for Pharmacovigilance], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/dt [Drug Therapy], trastuzumab/pv [Special Situation for Pharmacovigilance], valrubicin/ae [Adverse Drug Reaction], valrubicin/dt [Drug Therapy], valrubicin/pv [Special Situation for Pharmacovigilance], sorafenib/ae [Adverse Drug Reaction], adolescent, adult, article, Australia, cancer chemotherapy, cardiology, cardiotoxicity/di [Diagnosis], cardiotoxicity/si [Side Effect], cardiovascular magnetic resonance, child, childhood cancer/dt [Drug Therapy], clinical practice, cohort analysis, disease course, disease predisposition, drug safety, genetic variability, groups by age, health economics, heart failure, heart left ventricle failure, human, infant, information processing, maximal oxygen uptake, New Zealand, newborn, oncology, predictor variable, priority journal, bevacizumab/ae [Adverse Drug Reaction], bevacizumab/dt [Drug Therapy], bevacizumab/pv [Special Situation for Pharmacovigilance], daunorubicin/ae [Adverse Drug Reaction], daunorubicin/dt [Drug Therapy], daunorubicin/pv [Special Situation for Pharmacovigilance], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/dt [Drug Therapy], doxorubicin/pv [Special Situation for Pharmacovigilance], epirubicin/ae [Adverse Drug Reaction], epirubicin/dt [Drug Therapy], epirubicin/pv [Special Situation for Pharmacovigilance], idarubicin/ae [Adverse Drug Reaction], idarubicin/dt [Drug Therapy], idarubicin/pv [Special Situation for Pharmacovigilance], imatinib/ae [Adverse Drug Reaction], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27055Test
Internal Medicine Journal
Click here for full text options
LibKey Link

مصطلحات الفهرس: imatinib/dt [Drug Therapy], imatinib/pv [Special Situation for Pharmacovigilance], lapatinib/ae [Adverse Drug Reaction], lapatinib/dt [Drug Therapy], lapatinib/pv [Special Situation for Pharmacovigilance], sorafenib/dt [Drug Therapy], sorafenib/pv [Special Situation for Pharmacovigilance], sunitinib/ae [Adverse Drug Reaction], sunitinib/dt [Drug Therapy], sunitinib/pv [Special Situation for Pharmacovigilance], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/dt [Drug Therapy], trastuzumab/pv [Special Situation for Pharmacovigilance], valrubicin/ae [Adverse Drug Reaction], valrubicin/dt [Drug Therapy], valrubicin/pv [Special Situation for Pharmacovigilance], sorafenib/ae [Adverse Drug Reaction], adolescent, adult, article, Australia, cancer chemotherapy, cardiology, cardiotoxicity/di [Diagnosis], cardiotoxicity/si [Side Effect], cardiovascular magnetic resonance, child, childhood cancer/dt [Drug Therapy], clinical practice, cohort analysis, disease course, disease predisposition, drug safety, genetic variability, groups by age, health economics, heart failure, heart left ventricle failure, human, infant, information processing, maximal oxygen uptake, New Zealand, newborn, oncology, predictor variable, priority journal, bevacizumab/ae [Adverse Drug Reaction], bevacizumab/dt [Drug Therapy], bevacizumab/pv [Special Situation for Pharmacovigilance], daunorubicin/ae [Adverse Drug Reaction], daunorubicin/dt [Drug Therapy], daunorubicin/pv [Special Situation for Pharmacovigilance], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/dt [Drug Therapy], doxorubicin/pv [Special Situation for Pharmacovigilance], epirubicin/ae [Adverse Drug Reaction], epirubicin/dt [Drug Therapy], epirubicin/pv [Special Situation for Pharmacovigilance], idarubicin/ae [Adverse Drug Reaction], idarubicin/dt [Drug Therapy], idarubicin/pv [Special Situation for Pharmacovigilance], imatinib/ae [Adverse Drug Reaction], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27055Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: cyclophosphamide/ae [Adverse Drug Reaction], gastrointestinal obstruction/si [Side Effect], human, infection/si [Side Effect], International Prognostic Index, letter, male, multiple cycle treatment, neuropathy/si [Side Effect], overall survival, plasmablastic lymphoma/dt [Drug Therapy], plasmablastic lymphoma/rt [Radiotherapy], plasmablastic lymphoma/th [Therapy], pleura effusion/si [Side Effect], priority journal, relapse, remission, retrospective study, salvage therapy, survival rate, thrombocytopenia/si [Side Effect], treatment response, bortezomib/ae [Adverse Drug Reaction], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], bortezomib/iv [Intravenous Drug Administration], bortezomib/sc [Subcutaneous Drug Administration], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], daratumumab/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], ifosfamide/cb [Drug Combination], ifosfamide/dt [Drug Therapy], prednisone/ae [Adverse Drug Reaction], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], adult, atrioventricular block/si [Side Effect], autologous stem cell transplantation, cancer radiotherapy, cancer staging, catheter thrombosis/si [Side Effect], clinical article, drug efficacy, drug safety, febrile neutropenia/si [Side Effect], female, follow up, Letter

URL: British Journal of Haematology
Click here for full text options
LibKey Link

مصطلحات الفهرس: cancer survival, clinical outcome, comorbidity, drug efficacy, drug tolerability, follicular lymphoma/di [Diagnosis], follicular lymphoma/dt [Drug Therapy], human, immunoregulation, infection/si [Side Effect], maintenance therapy, medical decision making, nonhodgkin lymphoma/di [Diagnosis], nonhodgkin lymphoma/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], patient monitoring, patient preference, priority journal, progression free survival, review, second cancer/si [Side Effect], survival time, symptom, T cell depletion, treatment duration, treatment response, tumor volume, bendamustine/ae [Adverse Drug Reaction], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], CD20 antibody/cb [Drug Combination], CD20 antibody/dt [Drug Therapy], obinutuzumab/dt [Drug Therapy], prednisolone/ae [Adverse Drug Reaction], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], overall survival, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], lenalidomide/dt [Drug Therapy], advanced cancer/di [Diagnosis], age, asymptomatic disease/di [Diagnosis], Australia, cancer combination chemotherapy, cancer diagnosis, cancer immunotherapy, cancer recurrence, cancer staging, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35707Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: cyclophosphamide/ae [Adverse Drug Reaction], gastrointestinal obstruction/si [Side Effect], human, infection/si [Side Effect], International Prognostic Index, letter, male, multiple cycle treatment, neuropathy/si [Side Effect], overall survival, plasmablastic lymphoma/dt [Drug Therapy], plasmablastic lymphoma/rt [Radiotherapy], plasmablastic lymphoma/th [Therapy], pleura effusion/si [Side Effect], priority journal, relapse, remission, retrospective study, salvage therapy, survival rate, thrombocytopenia/si [Side Effect], treatment response, bortezomib/ae [Adverse Drug Reaction], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], bortezomib/iv [Intravenous Drug Administration], bortezomib/sc [Subcutaneous Drug Administration], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], daratumumab/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], ifosfamide/cb [Drug Combination], ifosfamide/dt [Drug Therapy], prednisone/ae [Adverse Drug Reaction], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], adult, atrioventricular block/si [Side Effect], autologous stem cell transplantation, cancer radiotherapy, cancer staging, catheter thrombosis/si [Side Effect], clinical article, drug efficacy, drug safety, febrile neutropenia/si [Side Effect], female, follow up, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36245Test
British Journal of Haematology
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: etoposide/dt [Drug Therapy], continuous infusion, disease course, drug tolerability, dyspnea/th [Therapy], facies, histiocytosis X/dt [Drug Therapy], human, jaw disease, lung biopsy, lung disease/dt [Drug Therapy], lung function, male, neutropenia/si [Side Effect], oxygen therapy, priority journal, remission, side effect/si [Side Effect], treatment outcome, acepromazine/cb [Drug Combination], acepromazine/dt [Drug Therapy], antineoplastic agent/cb [Drug Combination], antineoplastic agent/dt [Drug Therapy], cladribine/ae [Adverse Drug Reaction], cladribine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], cytabom/cb [Drug Combination], cytabom/dt [Drug Therapy], vincristine/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/ae [Adverse Drug Reaction], unclassified drug, prednisolone/dt [Drug Therapy], prednisolone/cb [Drug Combination], adult, alopecia/si [Side Effect], article, bone disease/dt [Drug Therapy], case report, clinical examination, clinical feature, computer assisted tomography, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32786Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: male, medical record review, mortality, multiple cycle treatment, priority journal, review, school child, vincristine/cb [Drug Combination], side effect/si [Side Effect], treatment outcome, virus reactivation, virus replication, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], entecavir/dt [Drug Therapy], lamivudine/dt [Drug Therapy], prednisone/ae [Adverse Drug Reaction], prednisone/cb [Drug Combination], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], screening test, adolescent, adult, aged, child, controlled study, female, hematologic malignancy/dt [Drug Therapy], hepatitis B/dt [Drug Therapy], hepatitis B/si [Side Effect], hepatitis B/di [Diagnosis], hepatitis B/pc [Prevention], human, immunosuppressive treatment, major clinical study, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30316Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: doxorubicin/ae [Adverse Drug Reaction], doxorubicin/do [Drug Dose], doxorubicin/dt [Drug Therapy], recombinant granulocyte colony stimulating factor/ae [Adverse Drug Reaction], recombinant granulocyte colony stimulating factor/ct [Clinical Trial], recombinant granulocyte colony stimulating factor/do [Drug Dose], recombinant granulocyte colony stimulating factor/dt [Drug Therapy], recombinant granulocyte colony stimulating factor/pd [Pharmacology], recombinant granulocyte colony stimulating factor/sc [Subcutaneous Drug Administration], doxorubicin/iv [Intravenous Drug Administration], adult respiratory distress syndrome/si [Side Effect], aged, anemia/si [Side Effect], article, bone marrow suppression/dt [Drug Therapy], bone marrow suppression/si [Side Effect], bone pain/si [Side Effect], bronchopneumonia/si [Side Effect], cancer radiotherapy, clinical trial, controlled clinical trial, adult, controlled study, disease duration, disease severity, dose response, double blind procedure, drug efficacy, drug information, drug safety, drug tolerability, febrile neutropenia/si [Side Effect], female, human, hypoxia/si [Side Effect], incidence, intermethod comparison, leukocyte count, major clinical study, male, malignant neoplastic disease/dt [Drug Therapy], malignant neoplastic disease/rt [Radiotherapy], medical documentation, multicenter study, neutropenia/dt [Drug Therapy], neutropenia/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], priority journal, randomized controlled trial, sepsis/si [Side Effect], thorax pain/si [Side Effect], thrombocytopenia/si [Side Effect], time, treatment outcome, docetaxel/ae [Adverse Drug Reaction], docetaxel/do [Drug Dose], docetaxel/dt [Drug Therapy], docetaxel/iv [Intravenous Drug Administration], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32704Test
Click here for full text options
LibKey Link